A paper published today in PLOS Computational Biology has reported on the benefits that could be gained through developing a universal
vaccine against the influenza virus.
Goji berry's supplementation is thought to enhance the protective effect of flu
vaccine against influenza virus.
Not exact matches
The Hep B
vaccine (or HBV) protects
against the
virus that causes hepatitis B; the DTaP
vaccine protects
against the
viruses that cause diphtheria, tetanus, and pertussis (whooping cough); the PCV (pneumococcal
vaccine) protects
against the cause of bacterial meningitis, pneumonia, and ear infections; the Hib
vaccine protects
against Haemophilus
influenzae type b bacteria (which can also cause bacterial meningitis, pneumonia, or epiglottitis); and the rotavirus oral
vaccine protects
against a
virus that causes the stomach flu.
The chess battle
against influenza will have to continue for a while longer, but for now hopes are high that playing the M2
vaccine might be the right strategy to checkmate the
virus.
These antibodies protect
against certain strains of
influenza virus in the
vaccine, but may not provide thorough protection
against other strains of flu that may be present.
Studies have shown that flu
vaccines work better at protecting
against influenza B or
influenza A H1N1
viruses than
influenza A H3N2.
Novartis announced in a press statement today that it has made the first batch of
vaccine against the A (H1N1)
influenza virus causing the swine flu pandemic.
Currently, seasonal flu
vaccines are designed to induce high levels of protective antibodies
against hemagglutinin (HA), a protein found on the surface of the
influenza virus that enables the
virus to enter a human cell and initiate infection.
Since the most severe infections are caused by
influenza type A and type B
viruses, the available
vaccines provide coverage
against these two types.
Kang's primary research focuses on designing and developing effective
vaccines against viral diseases such as
influenza virus and RSV, but he partnered with a university and research institutes in South Korea that wanted international collaborative projects to study if ginseng can be used to improve health and protect
against disease because of the potential benefit in fighting these
viruses.
Researchers at the Mailman School of Public Health and Columbia University Medical Center studied the impact of text message reminders for the second dose of
influenza vaccine required for many young children to protect them
against the
virus.
The transmissible
viruses were sensitive to the antiviral drug oseltamivir and reacted well with antisera raised
against H5
influenza vaccine strains.
When the researchers exposed chickens to lethal doses of the avian
influenza virus and the Newcastle
virus, birds inoculated with the recombinant
vaccine produced antibodies
against both
viruses, offering protection
against both diseases.
Protection of mice
against lethal challenge with 2009 H1N1
influenza A
virus by 1918 - like and classical swine H1N1 based
vaccines
The study relates to a particular type of
vaccine (killed)
against a particular
virus,
influenza, though the findings might hold true for other killed
vaccines and for those
vaccines consisting only of proteins produced by GM in bacteria, yeast or insect cells,
against diseases such as hepatitis B (HBV) and human papilloma
virus (HPV, the causative agent of cervical cancer).
Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and less
Influenza vaccines that better target the
influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and less
influenza surface protein called neuraminidase (NA) could offer broad protection
against various
influenza virus strains and less
influenza virus strains and lessen the...
As
vaccine recipients, we usually think only of the ability of the
vaccine to protect us
against a specific disease, but here the effects on the whole population and on the
influenza virus itself are being considered.
She noted that the Canadian researchers estimated that the flu
vaccine is 55 percent effective
against influenza B
viruses, which typically cause more infections late in the season.
«
Influenza yearly protection is important for preventing the flu,» said Spicehandler, who is co-chief of infectious diseases at Northern Westchester Hospital in Mount Kisco, N.Y. «Each year the
vaccine is made up of different strains to protect
against what
viruses are prevalent.»
FLULAVAL is an
influenza virus vaccine indicated for active immunization of adults 18 years of age and older
against influenza disease caused by
influenza virus subtypes A and type B contained in the
vaccine.
Introducing VANGUARD ® CIV H3N2 / H3N8, a bivalent canine flu
vaccine with demonstrated safety and efficacy for protection
against both highly contagious H3N2 and H3N8 strains of canine
influenza virus (CIV).
Non-structural protein 1 (NS1) truncated (NS1 - 126, NS1 - 99 and NS1 - 73) or deleted (DNS1) H3N8 canine
influenza viruses (CIVs) were tested for their safety, immunogenicity and protection efficacy as live - attenuated
influenza vaccines (LAIVs)
against wild - type (WT) H3N8 CIV.
FLORHAM PARK, N.J., Sept. 9, 2014 — Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that FLUVAC INNOVATOR ®, the first equine
influenza virus (EIV)
vaccine, can provide a demonstrated cross-reactive immune response
against emerging EIV strains.
«Zoetis offers a complete line of
vaccines for protection from common equine diseases, including WEST NILE - INNOVATOR ®, to help protect
against West Nile
virus, and FLUVAC INNOVATOR, to help protect
against equine
influenza virus and EHV - 1 and EHV - 4.
Evaluation of the ability of canarypox - vectored equine
influenza virus vaccines to induce humoral immune responses
against canine
influenza viruses in dogs.
«Pfizer Animal Health is committed to monitoring swine
influenza viruses and bringing to the market
vaccines that help protect
against SIV strains circulating in pork production systems today,» said Kuhn.
Vaccines against other respiratory causing pathogens, such as Bordetella, parainfluenza, and adenovirus, may help to prevent a secondary infection in a dog already compromised by the
influenza virus.
The specific strand of the
virus has been identified as H3N2
influenza, and we carry the
vaccine that protects your pet
against it.
We carry
vaccines that protect
against both strains of canine
influenza virus (H3N8 and H3N2) to help protect your pet.
Vanguard ® CIV H3N2 / H3N8 is a canine flu
vaccine that protects
against both strains of the canine
influenza virus.
Zoetis Inc. has started shipping Vanguard CIV H3N2 / H3N8, the company's newest
vaccine against canine
influenza virus.
Vaccines against the H3N8 influenza virus — which has existed in this country for more than a decade — are available, but there are differences in the genetic sequences of the two strains that suggest that these vaccines would be poorly effective, or ineffective in protecting dogs against the H3N2 virus infecting dogs in the Midwest
Vaccines against the H3N8
influenza virus — which has existed in this country for more than a decade — are available, but there are differences in the genetic sequences of the two strains that suggest that these
vaccines would be poorly effective, or ineffective in protecting dogs against the H3N2 virus infecting dogs in the Midwest
vaccines would be poorly effective, or ineffective in protecting dogs
against the H3N2
virus infecting dogs in the Midwest.»
This
vaccine pack provides comprehensive coverage
against two strains of the Canine
Influenza Virus — H3N8 and H3N2.
Fluvac Innovator ®
vaccines are the most trusted equine
influenza vaccines and help provide your horse with broad protection
against newly emerging and conventional equine
influenza virus strains as well as equine herpesvirus (EHV 1 and EHV 4).4 - 10 Zoetis regularly tests Fluvac Innovator to ensure its
vaccine continues to be effective
against emerging EIV isolates.
At this time, it is also unknown whether the current CIV
vaccine, developed to protect
against a different strain of the
virus (
Influenza A H3N8), will be effective in preventing
Influenza A H3N2.
So far, the H3N2
vaccine also shows promise in protecting
against the deadly H3N2 canine
influenza virus, which was first documented in United States in 2015.
The flu
vaccine protects
against the three
influenza viruses that are expected to be most prevalent each season, but there can be other flu
viruses circulating as well.
Vaccines also tend to be less effective
against A (H3N2) than other
influenza viruses.